Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 26, 2010

PolyTherics and Cantab Collaborate to Optimize Biologics

  • Leverton Licence Holdings (LLH), a subsidiary of Celtic Pharma’s Celtic Pharma Holdings II LIP (CP2) fund, is to invest in a biopharmaceuticals research program undertaken jointly by Cantab Biopharmaceuticals and PolyTherics. The announcement comes 24 hours after Celtic Pharma confirmed making a £5 million investment in Cantab to support the latter’s enhancement of off-patent biologics in the field of hematology.

    Cantab is a wholly owned subsidiary of CP2 and will work with PolyTherics, which specializes in the use of biomedical polymers to optimize therapeutics. PolyTherics’ technologies include its patented TheraPEG™ approach to the PEGylation of therapeutic proteins and antibody fragments.

    Through the collaboration PolyTherics will receive an up-front payment and ongoing technical support. LLH has an option to submit another two proteins for research into the collaboration.  LLH will also have an option to license products resulting from the joint research in return for paying PolyTherics a share of commercial sales.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »